| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 84 | 2019 | 1533 | 6.360 |
Why?
|
| Cell Transformation, Neoplastic | 21 | 2017 | 235 | 3.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2018 | 756 | 2.900 |
Why?
|
| Oncogenes | 12 | 2019 | 71 | 2.710 |
Why?
|
| ErbB Receptors | 25 | 2015 | 239 | 2.460 |
Why?
|
| Receptor, ErbB-2 | 20 | 2015 | 128 | 2.240 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2011 | 146 | 2.230 |
Why?
|
| Chromosomes, Human, Pair 8 | 8 | 2019 | 54 | 2.120 |
Why?
|
| Breast | 18 | 2016 | 137 | 2.020 |
Why?
|
| Glycoproteins | 10 | 2011 | 238 | 1.840 |
Why?
|
| Mammary Neoplasms, Experimental | 17 | 2018 | 114 | 1.730 |
Why?
|
| Cell Line, Tumor | 46 | 2019 | 1851 | 1.680 |
Why?
|
| Gene Amplification | 15 | 2019 | 71 | 1.560 |
Why?
|
| Epithelial Cells | 27 | 2009 | 431 | 1.520 |
Why?
|
| Tumor Cells, Cultured | 40 | 2017 | 852 | 1.410 |
Why?
|
| Epidermal Growth Factor | 18 | 2010 | 95 | 1.400 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2019 | 411 | 1.340 |
Why?
|
| Neoplasm Proteins | 13 | 2018 | 307 | 1.310 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2017 | 33 | 1.210 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2019 | 41 | 1.200 |
Why?
|
| Signal Transduction | 23 | 2018 | 2689 | 1.120 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 271 | 1.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2019 | 214 | 1.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 7 | 2015 | 19 | 0.970 |
Why?
|
| Cell Cycle Proteins | 4 | 2019 | 230 | 0.970 |
Why?
|
| Cell Division | 34 | 2010 | 541 | 0.910 |
Why?
|
| EGF Family of Proteins | 6 | 2014 | 17 | 0.910 |
Why?
|
| Phosphatidylinositol 3-Kinases | 8 | 2015 | 223 | 0.840 |
Why?
|
| Cell Proliferation | 16 | 2019 | 1174 | 0.810 |
Why?
|
| Mammary Glands, Human | 7 | 2012 | 33 | 0.800 |
Why?
|
| Mammary Glands, Animal | 13 | 2000 | 71 | 0.800 |
Why?
|
| Genes, erbB-2 | 7 | 2009 | 15 | 0.800 |
Why?
|
| Growth Substances | 11 | 1999 | 77 | 0.800 |
Why?
|
| Female | 85 | 2019 | 38021 | 0.790 |
Why?
|
| Quinazolines | 4 | 2019 | 70 | 0.750 |
Why?
|
| Cell Survival | 14 | 2016 | 901 | 0.750 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2016 | 100 | 0.740 |
Why?
|
| Humans | 113 | 2019 | 68549 | 0.740 |
Why?
|
| Phosphoproteins | 4 | 2019 | 202 | 0.730 |
Why?
|
| Antineoplastic Agents | 9 | 2017 | 1070 | 0.720 |
Why?
|
| Insulin-Like Growth Factor I | 9 | 2006 | 110 | 0.670 |
Why?
|
| Neoplasm Invasiveness | 13 | 2016 | 369 | 0.660 |
Why?
|
| Piperazines | 2 | 2019 | 206 | 0.640 |
Why?
|
| Pyrazoles | 1 | 2019 | 190 | 0.640 |
Why?
|
| Cell Line | 18 | 2016 | 1752 | 0.590 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.570 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 61 | 0.570 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2014 | 108 | 0.570 |
Why?
|
| Alternative Splicing | 3 | 2007 | 93 | 0.560 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 35 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 467 | 0.550 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 111 | 0.540 |
Why?
|
| Receptors, Estrogen | 7 | 2019 | 142 | 0.530 |
Why?
|
| Amphiregulin | 6 | 2014 | 19 | 0.530 |
Why?
|
| Small Molecule Libraries | 1 | 2016 | 53 | 0.530 |
Why?
|
| Insulin | 9 | 2011 | 617 | 0.530 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 65 | 0.510 |
Why?
|
| Gene Knockdown Techniques | 5 | 2019 | 196 | 0.510 |
Why?
|
| Chaperonin Containing TCP-1 | 1 | 2015 | 2 | 0.510 |
Why?
|
| Biomarkers, Tumor | 7 | 2015 | 508 | 0.500 |
Why?
|
| Estrogens | 1 | 2016 | 173 | 0.490 |
Why?
|
| Mutation | 10 | 2012 | 1213 | 0.490 |
Why?
|
| Histone Acetyltransferases | 1 | 2014 | 13 | 0.490 |
Why?
|
| RNA-Binding Proteins | 2 | 2006 | 215 | 0.490 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2010 | 710 | 0.490 |
Why?
|
| Receptors, Fibroblast Growth Factor | 3 | 2004 | 22 | 0.490 |
Why?
|
| Gene Expression Profiling | 10 | 2016 | 498 | 0.480 |
Why?
|
| RNA, Messenger | 11 | 2010 | 1663 | 0.480 |
Why?
|
| Phosphorylation | 11 | 2019 | 1200 | 0.480 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 57 | 0.470 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 10 | 2010 | 320 | 0.470 |
Why?
|
| Adenocarcinoma | 4 | 2011 | 475 | 0.460 |
Why?
|
| DNA Methylation | 4 | 2011 | 193 | 0.430 |
Why?
|
| Up-Regulation | 7 | 2016 | 682 | 0.430 |
Why?
|
| Gene Expression | 6 | 2015 | 770 | 0.420 |
Why?
|
| Animals | 49 | 2019 | 20880 | 0.420 |
Why?
|
| Transfection | 10 | 2019 | 782 | 0.420 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2011 | 5 | 0.400 |
Why?
|
| Mice | 27 | 2019 | 8474 | 0.400 |
Why?
|
| Autocrine Communication | 2 | 2008 | 37 | 0.390 |
Why?
|
| Phenotype | 10 | 2011 | 946 | 0.390 |
Why?
|
| Retinoblastoma Protein | 2 | 2002 | 75 | 0.390 |
Why?
|
| Enzyme Inhibitors | 7 | 2010 | 659 | 0.390 |
Why?
|
| Apoptosis | 7 | 2012 | 1641 | 0.380 |
Why?
|
| Ultraviolet Rays | 2 | 2002 | 130 | 0.380 |
Why?
|
| Transcription Factors | 5 | 2014 | 753 | 0.380 |
Why?
|
| Membrane Proteins | 4 | 2018 | 617 | 0.380 |
Why?
|
| RNA, Small Interfering | 6 | 2017 | 434 | 0.350 |
Why?
|
| Gene Silencing | 2 | 2009 | 137 | 0.350 |
Why?
|
| Wnt Proteins | 1 | 2009 | 57 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 624 | 0.340 |
Why?
|
| NF-kappa B | 3 | 2015 | 432 | 0.310 |
Why?
|
| beta Catenin | 2 | 2007 | 73 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 300 | 0.300 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2005 | 21 | 0.300 |
Why?
|
| RNA Interference | 4 | 2017 | 266 | 0.300 |
Why?
|
| Drug Synergism | 2 | 2019 | 260 | 0.300 |
Why?
|
| Feedback, Physiological | 1 | 2007 | 38 | 0.300 |
Why?
|
| Interleukin-1 | 1 | 2007 | 86 | 0.290 |
Why?
|
| DNA, Neoplasm | 8 | 2011 | 95 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 90 | 0.280 |
Why?
|
| Culture Media | 10 | 2006 | 155 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 3 | 2017 | 84 | 0.270 |
Why?
|
| Trans-Activators | 4 | 2004 | 237 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 332 | 0.270 |
Why?
|
| Cells, Cultured | 15 | 2009 | 2673 | 0.270 |
Why?
|
| Down-Regulation | 2 | 2009 | 447 | 0.270 |
Why?
|
| Human papillomavirus 16 | 1 | 2005 | 19 | 0.260 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2005 | 18 | 0.260 |
Why?
|
| Cyclin E | 2 | 2004 | 19 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 304 | 0.250 |
Why?
|
| Receptor, ErbB-3 | 5 | 2010 | 17 | 0.250 |
Why?
|
| Repressor Proteins | 2 | 2005 | 182 | 0.250 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2007 | 61 | 0.250 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2004 | 8 | 0.240 |
Why?
|
| Cell Culture Techniques | 2 | 2015 | 189 | 0.240 |
Why?
|
| F-Box Proteins | 1 | 2004 | 14 | 0.240 |
Why?
|
| Chromosomal Instability | 1 | 2004 | 14 | 0.240 |
Why?
|
| Carcinoma | 3 | 2011 | 215 | 0.240 |
Why?
|
| Protein Isoforms | 2 | 2007 | 246 | 0.240 |
Why?
|
| Radiation Tolerance | 2 | 2000 | 30 | 0.230 |
Why?
|
| Deoxyglucose | 5 | 1996 | 32 | 0.230 |
Why?
|
| Base Sequence | 9 | 2006 | 1015 | 0.230 |
Why?
|
| Nucleic Acid Hybridization | 4 | 2006 | 95 | 0.220 |
Why?
|
| Integrin alpha4 | 1 | 2003 | 3 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 7 | 2011 | 492 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 1172 | 0.220 |
Why?
|
| Prognosis | 3 | 2019 | 2093 | 0.220 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2014 | 30 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 250 | 0.210 |
Why?
|
| DNA-Binding Proteins | 5 | 2012 | 700 | 0.210 |
Why?
|
| Blotting, Western | 6 | 2010 | 954 | 0.210 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2004 | 35 | 0.200 |
Why?
|
| MCF-7 Cells | 2 | 2019 | 80 | 0.200 |
Why?
|
| Rats | 19 | 1996 | 5300 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 118 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2008 | 195 | 0.190 |
Why?
|
| Chemotactic Factors | 2 | 2016 | 14 | 0.190 |
Why?
|
| Epithelium | 10 | 1997 | 172 | 0.190 |
Why?
|
| Histones | 2 | 2012 | 111 | 0.190 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1033 | 0.190 |
Why?
|
| Neuregulin-1 | 1 | 2000 | 20 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2015 | 627 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2015 | 331 | 0.180 |
Why?
|
| Cell Line, Transformed | 4 | 2005 | 100 | 0.180 |
Why?
|
| Blotting, Northern | 4 | 2007 | 189 | 0.180 |
Why?
|
| Fibrocystic Breast Disease | 3 | 1984 | 7 | 0.180 |
Why?
|
| Epigenesis, Genetic | 3 | 2010 | 163 | 0.180 |
Why?
|
| Genes, myc | 2 | 2018 | 26 | 0.180 |
Why?
|
| Rats, Inbred Lew | 11 | 1996 | 150 | 0.170 |
Why?
|
| Phosphotyrosine | 5 | 1999 | 41 | 0.170 |
Why?
|
| Hyperplasia | 3 | 2017 | 89 | 0.170 |
Why?
|
| Tumor Burden | 1 | 2019 | 132 | 0.170 |
Why?
|
| Everolimus | 1 | 2019 | 26 | 0.170 |
Why?
|
| Thiophenes | 1 | 2019 | 76 | 0.170 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 37 | 0.170 |
Why?
|
| Genetic Therapy | 1 | 2001 | 291 | 0.170 |
Why?
|
| Disease Progression | 5 | 2013 | 1037 | 0.170 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 157 | 0.170 |
Why?
|
| Enzyme Activation | 6 | 2009 | 791 | 0.170 |
Why?
|
| Mitogens | 2 | 1996 | 45 | 0.160 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 2 | 2009 | 26 | 0.160 |
Why?
|
| DNA, Complementary | 3 | 2005 | 251 | 0.160 |
Why?
|
| Exons | 3 | 2011 | 122 | 0.160 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 57 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2019 | 128 | 0.160 |
Why?
|
| Molecular Sequence Data | 9 | 2008 | 1446 | 0.160 |
Why?
|
| Mucin-1 | 1 | 2018 | 35 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 349 | 0.160 |
Why?
|
| Recurrence | 2 | 2019 | 948 | 0.160 |
Why?
|
| Spheroids, Cellular | 2 | 2017 | 45 | 0.160 |
Why?
|
| Th1 Cells | 1 | 2018 | 101 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 3 | 2017 | 614 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 199 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 536 | 0.150 |
Why?
|
| Mice, Nude | 7 | 2016 | 294 | 0.150 |
Why?
|
| Phenanthrenes | 1 | 2017 | 18 | 0.150 |
Why?
|
| Diterpenes | 1 | 2017 | 42 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2018 | 116 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 110 | 0.140 |
Why?
|
| Vaccination | 1 | 2018 | 182 | 0.140 |
Why?
|
| Chemokine CXCL16 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Neuregulins | 5 | 1996 | 11 | 0.140 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 9 | 0.140 |
Why?
|
| Protein Transport | 2 | 2011 | 280 | 0.140 |
Why?
|
| Cancer Vaccines | 2 | 2018 | 61 | 0.140 |
Why?
|
| Cluster Analysis | 2 | 2014 | 219 | 0.140 |
Why?
|
| Lymphatic Metastasis | 3 | 1993 | 274 | 0.140 |
Why?
|
| Lactation | 1 | 2017 | 110 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2006 | 381 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 68 | 0.130 |
Why?
|
| DNA Primers | 3 | 2006 | 302 | 0.130 |
Why?
|
| Chromatin | 1 | 2016 | 76 | 0.130 |
Why?
|
| Monocytes | 1 | 2016 | 210 | 0.130 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 8 | 1997 | 14 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2014 | 130 | 0.130 |
Why?
|
| Cell Death | 1 | 2016 | 329 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 170 | 0.130 |
Why?
|
| Quality Control | 1 | 2015 | 81 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2016 | 326 | 0.130 |
Why?
|
| Chemokines | 1 | 2015 | 119 | 0.130 |
Why?
|
| Chromosome Mapping | 2 | 2006 | 188 | 0.130 |
Why?
|
| Tyrosine | 4 | 1998 | 196 | 0.130 |
Why?
|
| Carotenoids | 1 | 1995 | 45 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 114 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2007 | 134 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 444 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 1 | 1995 | 52 | 0.120 |
Why?
|
| Flow Cytometry | 5 | 2018 | 489 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 2 | 2016 | 384 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.120 |
Why?
|
| DNA Repair | 2 | 2007 | 127 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 200 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2011 | 23 | 0.120 |
Why?
|
| Fibroblast Growth Factor 7 | 2 | 2007 | 6 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 267 | 0.120 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2013 | 13 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2015 | 621 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 135 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2008 | 62 | 0.110 |
Why?
|
| Glutamine | 1 | 2013 | 45 | 0.110 |
Why?
|
| Fibronectins | 3 | 2004 | 130 | 0.110 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2011 | 6 | 0.110 |
Why?
|
| Genes, Neoplasm | 2 | 2011 | 18 | 0.110 |
Why?
|
| Transcription, Genetic | 3 | 2005 | 562 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2008 | 99 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.110 |
Why?
|
| Retroviridae | 3 | 2003 | 29 | 0.110 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2012 | 13 | 0.110 |
Why?
|
| Antibodies, Neoplasm | 1 | 2012 | 6 | 0.110 |
Why?
|
| Vaccines, DNA | 1 | 2012 | 9 | 0.110 |
Why?
|
| Cloning, Molecular | 2 | 2005 | 357 | 0.100 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2012 | 19 | 0.100 |
Why?
|
| Culture Media, Conditioned | 2 | 2006 | 78 | 0.100 |
Why?
|
| Imidazoles | 2 | 2003 | 175 | 0.100 |
Why?
|
| Genes, Reporter | 2 | 2010 | 191 | 0.100 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2012 | 99 | 0.100 |
Why?
|
| Morpholines | 3 | 2010 | 79 | 0.100 |
Why?
|
| Cyclic AMP | 2 | 1989 | 223 | 0.100 |
Why?
|
| Phosphoglycerate Dehydrogenase | 1 | 2011 | 1 | 0.100 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Protein Binding | 1 | 2014 | 1027 | 0.100 |
Why?
|
| In Vitro Techniques | 5 | 2010 | 765 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 560 | 0.100 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2011 | 34 | 0.100 |
Why?
|
| Transduction, Genetic | 2 | 2009 | 81 | 0.100 |
Why?
|
| Pyridines | 2 | 2003 | 261 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 10 | 0.090 |
Why?
|
| Genes, ras | 1 | 1991 | 46 | 0.090 |
Why?
|
| Blotting, Southern | 2 | 2004 | 67 | 0.090 |
Why?
|
| Somatomedins | 1 | 1990 | 16 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 94 | 0.090 |
Why?
|
| Carcinogens | 3 | 1998 | 86 | 0.090 |
Why?
|
| Lentivirus | 2 | 2007 | 35 | 0.090 |
Why?
|
| Transplantation, Heterologous | 4 | 2011 | 122 | 0.090 |
Why?
|
| Disulfiram | 1 | 2010 | 22 | 0.090 |
Why?
|
| Transforming Growth Factors | 1 | 1990 | 12 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 1990 | 33 | 0.090 |
Why?
|
| RNA, Neoplasm | 3 | 2000 | 76 | 0.090 |
Why?
|
| Ligands | 2 | 2015 | 317 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2009 | 3 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2005 | 144 | 0.090 |
Why?
|
| Protein Array Analysis | 2 | 2008 | 32 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2011 | 1549 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2009 | 13 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2014 | 447 | 0.090 |
Why?
|
| Genes, BRCA1 | 2 | 2007 | 47 | 0.090 |
Why?
|
| Glucose | 1 | 2011 | 307 | 0.080 |
Why?
|
| Cholera Toxin | 4 | 1991 | 30 | 0.080 |
Why?
|
| Immunoblotting | 3 | 2005 | 254 | 0.080 |
Why?
|
| Pyrimidines | 2 | 2007 | 178 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 8 | 2011 | 532 | 0.080 |
Why?
|
| Galectin 3 | 1 | 2008 | 8 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2009 | 58 | 0.080 |
Why?
|
| Editorial Policies | 1 | 2009 | 32 | 0.080 |
Why?
|
| Disclosure | 1 | 2009 | 45 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 20 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 43 | 0.080 |
Why?
|
| Blood Glucose | 1 | 1992 | 631 | 0.080 |
Why?
|
| Binding Sites | 2 | 2008 | 631 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2016 | 306 | 0.080 |
Why?
|
| Adenoviridae | 2 | 2018 | 295 | 0.080 |
Why?
|
| Androstadienes | 2 | 2000 | 41 | 0.080 |
Why?
|
| Cell Adhesion | 2 | 2004 | 324 | 0.080 |
Why?
|
| Ubiquitination | 1 | 2008 | 85 | 0.080 |
Why?
|
| ras Proteins | 2 | 2007 | 102 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 33 | 0.080 |
Why?
|
| Survival Rate | 1 | 2011 | 1055 | 0.080 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2005 | 13 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 1293 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 44 | 0.070 |
Why?
|
| Hormones | 1 | 1987 | 42 | 0.070 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Time Factors | 5 | 2005 | 4655 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2007 | 49 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 226 | 0.070 |
Why?
|
| Threonine | 1 | 2007 | 47 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 126 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2006 | 47 | 0.070 |
Why?
|
| src-Family Kinases | 2 | 2016 | 91 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 175 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 236 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2007 | 138 | 0.070 |
Why?
|
| Chemical Fractionation | 1 | 2006 | 18 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2007 | 220 | 0.070 |
Why?
|
| Cell Movement | 2 | 2006 | 630 | 0.070 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1996 | 30 | 0.070 |
Why?
|
| Fluorine Radioisotopes | 3 | 1996 | 13 | 0.070 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1985 | 8 | 0.070 |
Why?
|
| Histological Techniques | 1 | 1985 | 10 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 86 | 0.060 |
Why?
|
| NFI Transcription Factors | 1 | 2005 | 6 | 0.060 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2005 | 3 | 0.060 |
Why?
|
| Gene Library | 1 | 2005 | 68 | 0.060 |
Why?
|
| DNA Damage | 2 | 2005 | 190 | 0.060 |
Why?
|
| Integrin alpha4beta1 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.060 |
Why?
|
| Integrin alpha5beta1 | 1 | 2004 | 9 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2004 | 312 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2004 | 74 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2017 | 238 | 0.060 |
Why?
|
| Protein Biosynthesis | 1 | 2005 | 181 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 261 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2004 | 11 | 0.060 |
Why?
|
| Alleles | 1 | 2005 | 386 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 3 | 2004 | 86 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2004 | 161 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 108 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2004 | 144 | 0.060 |
Why?
|
| Calpain | 1 | 2004 | 205 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2003 | 38 | 0.060 |
Why?
|
| Genes, Dominant | 1 | 2003 | 51 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 1996 | 81 | 0.060 |
Why?
|
| Phagocytosis | 1 | 2003 | 65 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2000 | 89 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 507 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 272 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2003 | 84 | 0.050 |
Why?
|
| Cell Separation | 1 | 2003 | 132 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2006 | 310 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 6 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2002 | 31 | 0.050 |
Why?
|
| Caspase 8 | 1 | 2002 | 40 | 0.050 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 778 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2009 | 159 | 0.050 |
Why?
|
| Breast Diseases | 1 | 1982 | 40 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2004 | 483 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 194 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2003 | 222 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 1982 | 74 | 0.050 |
Why?
|
| Benzo(a)pyrene | 2 | 1998 | 7 | 0.050 |
Why?
|
| Actins | 1 | 2003 | 249 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 22 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 524 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 1999 | 311 | 0.050 |
Why?
|
| Polychlorinated Dibenzodioxins | 2 | 1998 | 38 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 1993 | 258 | 0.050 |
Why?
|
| Trastuzumab | 2 | 2015 | 17 | 0.050 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2000 | 13 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2000 | 114 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2002 | 546 | 0.050 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2000 | 48 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 194 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2000 | 51 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2000 | 234 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 1999 | 24 | 0.040 |
Why?
|
| Methylnitrosourea | 2 | 1991 | 9 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 1999 | 19 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 1999 | 46 | 0.040 |
Why?
|
| Collagen | 2 | 2016 | 636 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 174 | 0.040 |
Why?
|
| Floxuridine | 1 | 1999 | 20 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2008 | 231 | 0.040 |
Why?
|
| Immediate-Early Proteins | 1 | 1999 | 63 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 1999 | 27 | 0.040 |
Why?
|
| Middle Aged | 3 | 2011 | 21119 | 0.040 |
Why?
|
| Chromones | 2 | 2010 | 33 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2010 | 18 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 1999 | 20 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 77 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 1999 | 87 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2011 | 7028 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 61 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 376 | 0.040 |
Why?
|
| Models, Biological | 1 | 2003 | 981 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1174 | 0.040 |
Why?
|
| Estradiol | 1 | 1999 | 176 | 0.040 |
Why?
|
| Alprostadil | 2 | 1989 | 20 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 1082 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2004 | 160 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 80 | 0.040 |
Why?
|
| Wound Healing | 1 | 2000 | 260 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2550 | 0.040 |
Why?
|
| Calcium | 2 | 2004 | 929 | 0.040 |
Why?
|
| Pleural Effusion | 2 | 1996 | 74 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 1998 | 62 | 0.040 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 20 | 0.040 |
Why?
|
| Azacitidine | 2 | 2008 | 20 | 0.040 |
Why?
|
| Hydrocortisone | 2 | 1991 | 291 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 138 | 0.040 |
Why?
|
| S100 Proteins | 1 | 1997 | 42 | 0.040 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 1997 | 38 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 1997 | 51 | 0.040 |
Why?
|
| Gamma Rays | 4 | 1987 | 64 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2008 | 304 | 0.040 |
Why?
|
| Phospholipid Ethers | 1 | 1996 | 1 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 226 | 0.040 |
Why?
|
| Keratins | 2 | 1994 | 48 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 1996 | 30 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2000 | 493 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1996 | 10 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1996 | 15 | 0.040 |
Why?
|
| Solubility | 1 | 2016 | 134 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 1999 | 299 | 0.040 |
Why?
|
| RNA | 2 | 2004 | 171 | 0.030 |
Why?
|
| Leiomyoma | 1 | 1996 | 28 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 147 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 119 | 0.030 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 1996 | 99 | 0.030 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1996 | 54 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 266 | 0.030 |
Why?
|
| Vanadates | 1 | 1996 | 12 | 0.030 |
Why?
|
| G1 Phase | 2 | 2008 | 42 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 113 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 1996 | 282 | 0.030 |
Why?
|
| Chemokine CXCL2 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2016 | 57 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1996 | 73 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1996 | 73 | 0.030 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 21 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1996 | 56 | 0.030 |
Why?
|
| Radioimmunodetection | 1 | 1995 | 1 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 40 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2015 | 71 | 0.030 |
Why?
|
| Tritium | 1 | 1995 | 101 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 2791 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1995 | 27 | 0.030 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2015 | 34 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 19 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 115 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 302 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 213 | 0.030 |
Why?
|
| beta Carotene | 1 | 1995 | 16 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2008 | 137 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 1997 | 206 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 31 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2014 | 42 | 0.030 |
Why?
|
| Furans | 1 | 1995 | 27 | 0.030 |
Why?
|
| Male | 4 | 2011 | 37283 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 63 | 0.030 |
Why?
|
| Kinetics | 1 | 1996 | 1047 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 1997 | 1034 | 0.030 |
Why?
|
| Skin | 1 | 1997 | 451 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2000 | 694 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 1984 | 79 | 0.030 |
Why?
|
| Hybrid Cells | 1 | 1993 | 18 | 0.030 |
Why?
|
| Karyotyping | 1 | 1993 | 74 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2004 | 84 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2077 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1997 | 375 | 0.030 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2012 | 7 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2012 | 13 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2015 | 384 | 0.030 |
Why?
|
| BALB 3T3 Cells | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2007 | 155 | 0.030 |
Why?
|
| Immune Sera | 1 | 2012 | 30 | 0.030 |
Why?
|
| Methylation | 1 | 2012 | 56 | 0.030 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 40 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 65 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 27 | 0.030 |
Why?
|
| Endoribonucleases | 1 | 2012 | 22 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2008 | 282 | 0.030 |
Why?
|
| DNA | 2 | 2004 | 597 | 0.030 |
Why?
|
| Glutathione | 1 | 2013 | 343 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 19 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 51 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 51 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 38 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2011 | 82 | 0.020 |
Why?
|
| Codon | 1 | 1991 | 21 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 241 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 499 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 97 | 0.020 |
Why?
|
| Neoplasms | 1 | 2002 | 1664 | 0.020 |
Why?
|
| Receptors, Somatomedin | 1 | 1990 | 7 | 0.020 |
Why?
|
| Poly A | 1 | 1990 | 14 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 89 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 240 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 2004 | 305 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 490 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 481 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1990 | 248 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 54 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 61 | 0.020 |
Why?
|
| Copper | 1 | 2010 | 149 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2008 | 5 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 648 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2008 | 15 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 597 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2007 | 16 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2008 | 41 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 597 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2008 | 63 | 0.020 |
Why?
|
| Laminin | 1 | 2007 | 62 | 0.020 |
Why?
|
| Ethanolamine | 1 | 1987 | 1 | 0.020 |
Why?
|
| Bucladesine | 1 | 1987 | 8 | 0.020 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1987 | 18 | 0.020 |
Why?
|
| Prolactin | 1 | 1987 | 61 | 0.020 |
Why?
|
| Ethanolamines | 1 | 1987 | 33 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2007 | 103 | 0.020 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2007 | 14 | 0.020 |
Why?
|
| Indoles | 1 | 2008 | 146 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 141 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 503 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 1753 | 0.020 |
Why?
|
| Transferrin | 1 | 1987 | 94 | 0.020 |
Why?
|
| Genotype | 1 | 2008 | 785 | 0.020 |
Why?
|
| Progesterone | 1 | 1987 | 115 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2007 | 230 | 0.020 |
Why?
|
| Autoradiography | 2 | 1996 | 94 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 1996 | 166 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 247 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 122 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 282 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 53 | 0.020 |
Why?
|
| Genomics | 1 | 2006 | 168 | 0.020 |
Why?
|
| Telomere | 1 | 2005 | 59 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2001 | 1465 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 848 | 0.020 |
Why?
|
| Basement Membrane | 1 | 2004 | 48 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2004 | 6 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2004 | 5 | 0.020 |
Why?
|
| Ionomycin | 1 | 2004 | 24 | 0.020 |
Why?
|
| Internet | 1 | 2007 | 390 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 1341 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1984 | 144 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2004 | 10 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 37 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 88 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 37 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 69 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2004 | 66 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 81 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 105 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2003 | 151 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 729 | 0.010 |
Why?
|
| Diuretics, Osmotic | 1 | 2001 | 5 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 35 | 0.010 |
Why?
|
| Mannitol | 1 | 2001 | 25 | 0.010 |
Why?
|
| Mad2 Proteins | 1 | 2000 | 3 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2000 | 8 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2001 | 67 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 150 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 358 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 147 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2000 | 41 | 0.010 |
Why?
|
| Receptors, Fibronectin | 1 | 2000 | 6 | 0.010 |
Why?
|
| Mice, Obese | 1 | 2000 | 33 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2000 | 36 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2001 | 109 | 0.010 |
Why?
|
| Keratinocytes | 1 | 2000 | 68 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 511 | 0.010 |
Why?
|
| rhoC GTP-Binding Protein | 1 | 1999 | 1 | 0.010 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 1999 | 3 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 140 | 0.010 |
Why?
|
| S Phase | 1 | 1999 | 38 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 1999 | 76 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 1999 | 42 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 60 | 0.010 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1998 | 15 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 475 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2001 | 306 | 0.010 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 1998 | 26 | 0.010 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1998 | 42 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 124 | 0.010 |
Why?
|
| Swine | 1 | 1999 | 672 | 0.010 |
Why?
|
| Benzoflavones | 1 | 1997 | 1 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1997 | 24 | 0.010 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1997 | 40 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1995 | 10 | 0.010 |
Why?
|
| Beta Particles | 1 | 1995 | 7 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 22 | 0.010 |
Why?
|
| Homeostasis | 1 | 1997 | 291 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1995 | 91 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2000 | 902 | 0.010 |
Why?
|
| Proteins | 1 | 1998 | 473 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1995 | 189 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1994 | 11 | 0.010 |
Why?
|
| Equipment Design | 1 | 1995 | 500 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1995 | 652 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1994 | 168 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1993 | 65 | 0.010 |
Why?
|
| Macrophages | 1 | 1995 | 647 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1990 | 40 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 532 | 0.010 |
Why?
|
| Reference Values | 1 | 1990 | 579 | 0.010 |
Why?
|
| Adult | 1 | 2006 | 21379 | 0.000 |
Why?
|
| Cesium Radioisotopes | 1 | 1984 | 15 | 0.000 |
Why?
|
| Whole-Body Irradiation | 1 | 1984 | 52 | 0.000 |
Why?
|